Background pattern of a brain with neural connections
Jennifer Johnston

Jennifer Johnston

Co-PI (Core Leadership)

NysnoBio

Dr. Johnston has been studying neurodegenerative disease for the last 20 years, starting with her work with Dr. R. Kopito at Stanford which resulted in the discovery of Aggresomes. At Elan Pharmaceuticals, Dr. Johnston studied protein folding and cellular proteostasis for basic research and drug discovery for PD. In addition to VP Head of Exploratory Research, Dr. Johnston also identified small molecule therapeutics for Parkin E3 ligase, reported the first high resolution crystal structure of the Parkin protein, and determined Parkin functions as a new category of ligase. Presently, Dr. Johnston is Co-Founder and CEO of NysnoBio, a Biotech company focused on the modulation of the Parkin enzyme pathway for critical unmet medical needs in Neurology and Oncology.

Recent ASAP Preprints & Published Papers

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.